Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Calydon

M&A STATUS
M&A LATEST DEAL TYPE
$17.7M LATEST DEAL AMOUNT
Description

Developer of therapeutic products for cancer. The company is focused on the development and commercialization of innovative therapeutic products for cancer based on gene therapy technologies.

Website
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Acquirer
Primary Office
  • 1331 Hillview Drive
  • Menlo Park, CA 94025
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Calydon’s full profile, request a free trial.

Calydon Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 05-Sep-2001 $17.7M 000.00 000.00 Completed Clinical Trials - Phase 2
2. Early Stage VC 11-Dec-1997 000.00 000.00 Completed Product Development
1. Early Stage VC $3.8M $3.8M Completed
To view this company’s complete deal history including valuation and funding, request access »

Calydon Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
AmBex Venture Partners Venture Capital Minority 000 0000 000000 0
Genesis Merchant Partners Lender/Debt Provider Minority 000 0000 000000 0
Lord Rothschild Angel (individual) Minority 000 0000 000000 0
Perseus (Bethesda) PE/Buyout Minority 000 0000 000000 0
Sequoia Capital Venture Capital Minority 000 0000 000000 0